Description

HYNIC-PSMA is a specialized ligand designed for molecular imaging and prostate cancer research. It integrates two distinct but complementary functional groups: HYNIC (6-hydrazinonicotinamide), which serves as a chelator enabling the attachment of radioactive isotopes, and PSMA (Prostate-Specific Membrane Antigen), a highly expressed surface antigen found predominantly on prostate cancer cells.

This dual-component design makes HYNIC-PSMA a versatile tool in oncology research. By allowing conjugation with isotopes such as ^188Re or ^99mTc, it enables the synthesis of radionuclide-drug conjugates (RDCs) and targeted imaging agents for tumors that overexpress PSMA.

Manufactured under strict GMP compliance, HYNIC-PSMA achieves a purity level of 99.81%, ensuring reproducibility and reliability for both preclinical and translational studies. Its unique molecular profile has made it a valuable reagent in investigating new diagnostic and therapeutic approaches in prostate cancer biology, especially where precise tumor visualization and targeted delivery systems are essential.

The ability to radiolabel HYNIC-PSMA not only supports imaging techniques like SPECT and PET but also offers opportunities for therapeutic applications by enabling selective delivery of radioisotopes to cancer cells. This dual-purpose nature situates HYNIC-PSMA as a bridge between imaging and therapy research, advancing the development of theranostic models in oncology.

Product Specifications

Mechanism of Action & Research Applications

HYNIC-PSMA functions through its dual-role mechanism:

1. Targeting Moiety (PSMA):

   • PSMA is a cell-surface antigen that is strongly expressed in prostate cancer tissues and to a lesser extent in other malignancies such as renal carcinoma or certain salivary gland tumors.

   • The PSMA component in HYNIC-PSMA ensures selective binding to prostate cancer cells, making it an effective targeting ligand for imaging and therapeutic research.

2. Chelation Moiety (HYNIC):

   • HYNIC acts as a bifunctional chelating agent that can stably bind various radionuclides (e.g., ^188Re, ^99mTc).

   • This feature allows researchers to radiolabel HYNIC-PSMA for use in PET or SPECT imaging, enabling high-contrast visualization of tumors.

Research Applications:

• Molecular Imaging: When labeled with ^68Ga, HYNIC-PSMA facilitates PET imaging of prostate tumors, aiding in localization, staging, and monitoring treatment responses.

• Radionuclide-Drug Conjugates (RDCs): By coupling isotopes to HYNIC-PSMA, researchers can investigate targeted delivery systems that selectively irradiate cancer cells while sparing healthy tissues.

• Oncology Research: Beyond diagnostics, it provides a platform for developing theranostic approaches that combine imaging and therapy.

• Prostate Cancer Biology: Serves as a reliable tool for studying PSMA expression patterns, tumor aggressiveness, and potential mechanisms of resistance.

This makes HYNIC-PSMA highly valuable in preclinical pipelines exploring both diagnostic radiopharmaceuticals and targeted therapeutic strategies.

Side Effects (For Reference in Models)

While HYNIC-PSMA itself is a research compound and not intended for clinical use, insights can be drawn from studies involving PSMA-targeted radioligands:

• Potential off-target accumulation in salivary glands and kidneys due to natural PSMA expression.

• Possible cytotoxicity depending on the radionuclide chosen for labeling.

• Radiation-associated side effects in models using therapeutic isotopes.

These observations underscore the importance of careful dosing, isotope selection, and controlled experimental conditions.

Disclaimer

 is supplied strictly for laboratory research use only. It is not intended for human use, clinical diagnosis, or therapeutic applications. All research applications must be conducted by qualified professionals under appropriate laboratory conditions.

Keywords

• CAS 2213408-17-2

• GMP peptide supplier

• PSMA ligand research

• Prostate cancer imaging ligand

• Radionuclide-drug conjugates (RDCs)

• PET SPECT imaging peptides

• High-purity oncology research compounds

• PSMA-targeting molecules

• Radiolabeled prostate cancer ligands